HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Chairman Nominee Majoras Represented Aventis In Price-Fixing Case

This article was originally published in The Tan Sheet

Executive Summary

FTC chairman nominee Deborah Majoras offers an extensive background in antitrust litigation, including work on vitamin price-fixing, to her new role at the agency

You may also be interested in...



FTC administrators

Deborah Majoras "is a highly talented and experienced lawyer, and will be an excellent chairman" of the Federal Trade Commission, Timothy Muris says of his successor in a recent statement. Muris' resignation as FTC chairman takes effect Aug. 15; Majoras' nomination was announced in May (1"The Tan Sheet" May 17, 2004, p. 14)...

Supreme Court Ponders U.S. Reach In Vitamin Antitrust Case Oral Arguments

Allowing antitrust claims in U.S. courts for injuries sustained in foreign commerce will weaken amnesty programs designed to detect international cartels, the government argued before the Supreme Court April 26 in a longstanding vitamin antitrust price-fixing case

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS128608

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel